Hypo-fractionated Stereotactic Body Radiotherapy for Localized Prostate Cancer

Completed

Conditions studied: Prostate Cancer

In brief

This is an observational study in which a questionnaire is used to obtain quality of life data after patients undergo a hypo-fractionated course of stereotactic body radiotherapy (SBRT) for the treatment of their prostate cancer. The SBRT itself is considered standard of care for these patients and as such, is not an official component of the study.

Key facts

Study ID: NCT01059513
Run by: Jonsson Comprehensive Cancer Center
People needed: 167
Starts: 2010-01-26
Expected to finish: 2020-03-19
Last updated by the study team: 2020-11-25

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

Eligible patients will have clinical stage T1c, T2a, or T2b, a pre-biopsy PSA level <10 ng/mL and a biopsy Gleason score of 3+3 (or 3+4 if fewer than 30% of biopsy cores are involved).
The ability to understand and willingness to sign a written informed consent are necessary.

You may not qualify if…

Patients with tumor parameters that fall outside of the inclusion criteria.
Patients with evidence on imagining (bone scan, CT, or MRI) suggestive of disseminated disease.
Patients who have had any form of prior prostate treatment (surgery, radiotherapy, cryotherapy, high intensity focused ultrasound, TURP).
A prior course of hormone therapy (androgen deprivation) of greater than 3 months duration.
The use of other concurrent investigational agents.
There are no exclusions due to co-morbid disease or illnesses except for patients with severe inflammatory bowel disease.
No life expectancy restrictions will apply.
Performance status will not be considered.

Where it is running

UCLA Jonsson Comprehensive Cancer Center — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.